Core Viewpoint - The company,药捷安康, is set to launch an IPO with a global offering of 15.281 million H-shares at a price of HKD 13.15 per share, aiming to raise approximately HKD 201 million, with listing expected on June 23, 2025 [1][3]. Company Overview -药捷安康, established in April 2014, focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular diseases [5]. - The company has developed a pipeline that includes one core product and five clinical-stage candidates, along with one preclinical candidate [5]. Financial Highlights - The total amount raised from cornerstone investors is approximately HKD 149 million, with notable investors including Jiangbei Pharmaceutical and Kangfang Biotech [3]. - For the years 2023 and 2024, the company reported net losses of approximately RMB 343.39 million and RMB 274.61 million, respectively [7]. Research and Development - The core product, Tinengotinib, is a multi-target kinase inhibitor currently undergoing two pivotal clinical trials for cholangiocarcinoma [5][6]. - The R&D costs for 2023 and 2024 are estimated at RMB 344.75 million and RMB 244.00 million, representing 89.8% and 83.6% of total operating expenses, respectively [6].
药捷安康开启申购，将在港交所上市，募资总额约2亿港元